Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages 1047-1060

  Dearnaley, David ^a,b   Syndikus, Isabel ^c   Mossop, Helen ^a   Khoo, Vincent ^a,b   Birtle, Alison ^d   Bloomfield, David ^e   Graham, John ^f   Kirkbride, Peter ^g   Logue, John ^h   Malik, Zafar ^c   Money Kyrle, Julian ⁱ   O'Sullivan, Joe M ^j   Panades, Miguel ^k   Parker, Chris ^a,b   Patterson, Helen ^l   Scrase, Christopher ^m   Staffurth, John ⁿ   Stockdale, Andrew ^o   Tremlett, Jean ^e   Bidmead, Margaret ^b   Mayles, Helen ^c   Naismith, Olivia ^b   South, Chris ⁱ   Gao, Annie ^a,b   Cruickshank, Clare ^a   Hassan, Shama ^a   Pugh, Julia ^a   Griffin, Clare ^a   Hall, Emma ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d ROYAL PRESTON HOSPITAL   (United Kingdom)

^e Worthing Hospital   (United Kingdom)

^f MUSGROVE PARK HOSPITAL   (United Kingdom)

^g SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k LINCOLN COUNTY HOSPITAL   (United Kingdom)

^l ADDENBROOKE S HOSPITAL   (United Kingdom)

^m IPSWICH HOSPITAL   (United Kingdom)

ⁿ VELINDRE CANCER CENTRE   (United Kingdom)

^o UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLADDER DISEASE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CONVENTIONAL RADIOTHERAPY; ENTEROPATHY; FOLLOW UP; GAMMA RADIATION; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE HYPOFRACTIONATION; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84995969003     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30102-4     Document Type: Article

References (35)

1. 1 Cancer Research UK. Prostate cancer statistics – key facts. http://info.cancerresearchuk.org/cancerstats/keyfacts/prostate-cancer/, 2015 (accessed Feb 1, 2016).
2. 2 Soerjomataram, I, Lortet-Tieulent, J, Parkin, DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380 (2012), 1840–1850.
3. 3 NCCN clinical practice guidelines in oncology (NCCN guidelines) for prostate cancer. http:\www.nccn.org, 2011 (accessed Feb 1, 2016).
4. 4 Wolff, RF, Ryder, S, Bossi, A, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer 51 (2015), 2345–2367.
5. 5 Zaorsky, NG, Ohri, N, Showalter, TN, Dicker, AP, Den, RB, Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev 39 (2013), 728–736.
6. 6 Dearnaley, DP, Jovic, G, Syndikus, I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15 (2014), 464–473.
7. 7 National Institute for Health and Care Excellence. National Institute for Health and Care Excellence (NICE) clinical guideline: prostate cancer: diagnosis and treatment (CG175). http://www.nice.org.uk/guidance/cg175, 2014 (accessed Feb 1, 2016).
8. 8 Hou, Z, Li, G, Bai, S, High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J Cancer Res Clin Oncol 141 (2015), 1063–1071.
9. 9 Brenner, DJ, Martinez, AA, Edmundson, GK, Mitchell, C, Thames, HD, Armour, EP, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002), 6–13.
10. 10 Fowler, J, Chappell, R, Ritter, M, Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001), 1021–1031.
11. 11 Khoo, VS, Dearnaley, DP, Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clin Oncol (R Coll Radiol) 20 (2008), 12–14.
12. 12 Thames, HD, Bentzen, SM, Turesson, I, Overgaard, M, Van den Bogaert, W, Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 19 (1990), 219–235.
13. 13 Dearnaley, D, Syndikus, I, Sumo, G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13 (2012), 43–54.
14. 14 Roach, M 3rd, Marquez, C, Yuo, HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994), 33–37.
15. 15 Diaz, A, Roach, M 3rd, Marquez, C, et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994), 323–329.
16. 16 South, CP, Khoo, VS, Naismith, O, Norman, A, Dearnaley, DP, A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) 20 (2008), 15–21.
17. 17 LENT SOMA tables. Radiother Oncol 35 (1995), 17–60.
18. 18 Dearnaley, DP, Sydes, MR, Langley, RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 (2007), 31–41.
19. 19 Cox, JD, Stetz, J, Pajak, TF, Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995), 1341–1346.
20. 20 Wilkins, A, Mossop, H, Syndikus, I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16 (2015), 1605–1616.
21. 21 Roach, M 3rd, Hanks, G, Thames, H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006), 965–974.
22. 22 Koontz, BF, Bossi, A, Cozzarini, C, Wiegel, T, D'Amico, A, A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68 (2015), 683–691.
23. 23 Tree, AC, Alexander, EJ, Van As, NJ, Dearnaley, DP, Khoo, V, Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?. Clin Oncol (R Coll Radiol) 25 (2013), 483–498.
24. 24 Proust-Lima, C, Taylor, JM, Secher, S, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79 (2011), 195–201.
25. 25 Miralbell, R, Roberts, SA, Zubizarreta, E, Hendry, JH, Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta=1·4 (0·9–2·2) Gy. Int J Radiat Oncol Biol Phys 82 (2012), e17–e24.
26. 26 Vogelius, IR, Bentzen, SM, Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Physs 85 (2013), 89–94.
27. 27 Dasu, A, Toma-Dasu, I, Prostate alpha/beta revisited–an analysis of clinical results from 14 168 patients. Acta Oncol 51 (2012), 963–974.
28. 28 Zaorsky, NG, Palmer, JD, Hurwitz, MD, Keith, SW, Dicker, AP, Den, RB, What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115 (2015), 295–300.
29. 29 Arcangeli, G, Fowler, J, Gomellini, S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 79 (2011), 1013–1021.
30. 30 Pollack, A, Walker, G, Horwitz, EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31 (2013), 3860–3868.
31. 31 Hoffman, KE, Voong, KR, Pugh, TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88 (2014), 1074–1084.
32. 32 Aluwini, S, Pos, F, Schimmel, E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.
33. 33 Norkus, D, Karklelyte, A, Engels, B, et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol, 8, 2013, 206.
34. 34 Syndikus, I, Morgan, RC, Sydes, MR, Graham, JD, Dearnaley, DP, Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 77 (2010), 773–783.
35. 35 Round, CE, Williams, MV, Mee, T, et al. Radiotherapy demand and activity in England 2006–2020. Clin Oncol (R Coll Radiol) 25 (2013), 522–530.